It’s been a crucial week for Becton Dickinson and Co (NYSE:BDX); here’s what analysts have to say.

July 18, 2017 - By Linda Rogers

 It's been a crucial week for Becton Dickinson and Co (NYSE:BDX); here's what analysts have to say.
Investors sentiment increased to 0.92 in Q4 2016. Its up 0.02, from 0.9 in 2016Q3. It increased, as 52 investors sold Becton Dickinson and Co shares while 352 reduced holdings. 99 funds opened positions while 273 raised stakes. 169.86 million shares or 0.23% less from 170.25 million shares in 2016Q3 were reported.
Blackrock Ltd Liability Co reported 0.31% of its portfolio in Becton Dickinson and Co (NYSE:BDX). Newfocus Fin Ltd Liability Company holds 2.99% of its portfolio in Becton Dickinson and Co (NYSE:BDX) for 26,833 shares. Comerica Savings Bank holds 97,276 shares or 0.13% of its portfolio. Capstone Asset Management invested 0.12% of its portfolio in Becton Dickinson and Co (NYSE:BDX). Iab Financial Bank reported 0.2% stake. Lpl Fincl Lc, California-based fund reported 15,760 shares. 21,503 are owned by Natixis. Azimuth Cap Management Limited Liability Corp invested in 37,449 shares or 0.53% of the stock. Nichols Asset Mngmt Limited Com holds 4,912 shares. Amg National Trust Bank & Trust, Colorado-based fund reported 9,479 shares. 166,426 were reported by Ameriprise Fincl. British Columbia Inv Management Corporation owns 109,456 shares. Bank Of Stockton reported 7,179 shares. Massmutual Fsb Adv stated it has 0% in Becton Dickinson and Co (NYSE:BDX). Ontario – Canada-based Hillsdale Investment has invested 0% in Becton Dickinson and Co (NYSE:BDX).

Since February 14, 2017, it had 0 insider buys, and 3 insider sales for $12.53 million activity. The insider SHERMAN JEFFREY S sold $5.66M. 8,500 shares valued at $1.51M were sold by Conroy Alexandre on Tuesday, February 14.

Becton Dickinson and Co (NYSE:BDX) Ratings Coverage

Among 13 analysts covering Becton Dickinson (NYSE:BDX), 6 have Buy rating, 1 Sell and 6 Hold. Therefore 46% are positive. Becton Dickinson had 23 analyst reports since August 7, 2015 according to SRatingsIntel. RBC Capital Markets maintained Becton Dickinson and Co (NYSE:BDX) rating on Monday, July 10. RBC Capital Markets has “Hold” rating and $19300 target. Jefferies maintained Becton Dickinson and Co (NYSE:BDX) on Thursday, March 30 with “Buy” rating. Citigroup initiated Becton Dickinson and Co (NYSE:BDX) on Thursday, November 12 with “Neutral” rating. Citigroup downgraded the shares of BDX in report on Friday, September 23 to “Sell” rating. As per Monday, January 4, the company rating was downgraded by Morgan Stanley. The stock has “Sector Perform” rating by RBC Capital Markets on Friday, August 7. The stock of Becton Dickinson and Co (NYSE:BDX) earned “Strong Buy” rating by Raymond James on Friday, June 30. Cowen & Co maintained it with “Buy” rating and $23000 target in Monday, July 10 report. Citigroup maintained the shares of BDX in report on Thursday, February 4 with “Neutral” rating. The firm has “Buy” rating by Jefferies given on Friday, June 9. Below is a list of Becton Dickinson and Co (NYSE:BDX) latest ratings and price target changes.

10/07/2017 Broker: RBC Capital Markets Rating: Hold New Target: $193.0000 Maintain
10/07/2017 Broker: Cowen & Co Rating: Buy New Target: $230.0000 Maintain
09/06/2017 Broker: Jefferies Rating: Buy New Target: $200.0000 Maintain
30/06/2017 Broker: Raymond James Old Rating: Outperform New Rating: Strong Buy Upgrade
30/03/2017 Broker: Jefferies Rating: Buy New Target: $200.00 Maintain

The stock decreased 0.31% or $0.63 on July 17, reaching $199.99. About shares traded. Becton Dickinson and Co (NYSE:BDX) has risen 12.32% since July 18, 2016 and is uptrending. It has underperformed by 4.38% the S&P500.

Becton, Dickinson and Company is a global medical technology firm engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The company has market cap of $45.07 billion. The Firm operates through two divisions: BD Medical and BD Life Sciences. It has a 33.13 P/E ratio. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

More notable recent Becton Dickinson and Co (NYSE:BDX) news were published by: Nasdaq.com which released: “YieldBoost Becton, Dickinson & Co From 1.5% To 9.9% Using Options” on June 21, 2017, also Law360.com with their article: “Bard Investors Sue To Stop $24B Becton Dickinson Merger” published on June 22, 2017, Nasdaq.com published: “What Drove Becton, Dickinson (BDX) to a New 52-Week High?” on June 28, 2017. More interesting news about Becton Dickinson and Co (NYSE:BDX) were released by: Prnewswire.com and their article: “BD Receives FDA 510(k) Clearance for New Line of Customizable, 3.0mm Micro …” published on June 20, 2017 as well as Gurufocus.com‘s news article titled: “Waverton Investment Management Ltd Buys Becton, Dickinson and Co, Honeywell …” with publication date: July 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.